| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Departments of Biochemistry II [N. K., T. W., A. H., M. Y.], Surgery I [T. A.], and Pathology II [O. M.], National Defense Medical College, Saitama 359-8513; Departments of Microbiology and Molecular Virology [A. R., S. H., K. Tan., M. Shu.] and Surgery I [N. G.], Tokyo Medical Dental University, Tokyo 113-8519; Department of Surgery, Oita Red Cross Hospital [K. Tak.] Oita, 870-0033; and Fujiyakuhin Corporation Limited [M. Shi.], Saitama 331-8508, Japan
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B by hepatitis B virus factors (18
, 19)
; and repression or mutation of the p53 antioncogene (6
, 20)
. However, these findings are, in most cases, dependent on precedent knowledge based on oncogene analysis in other types of cancer. Therefore, the wide variety of genetic differences between HCC and nontumorous liver remain to be elucidated. Velculescu et al. (21)
have reported a method called serial analysis of gene expression to analyze the qualitative and quantitative aspects of mRNA expression. Using this technique, we identified several cDNAs that were differentially expressed in human HCC and nontumorous liver as well as in normal liver tissues. In this report, we evaluated some of these genes using surgical specimens and HCC cell lines. Our results suggest that the expression of these genes could be an index for evaluating differentiation, proliferation, and premalignant status in liver malignancy. |
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
) were used. Histological grades of HCC tissues were as follows: patient 5, well to moderately differentiated (Edmondson I or II); patients 1 and 4, moderately differentiated (Edmondson II); and patients 2 and 3, moderate to poorly differentiated (Edmondson II or III). Nontumorous liver tissues from patients 1–4 had cirrhosis associated with HCV infection. Patient 5 also had liver cirrhosis, but neither HCV nor HBV infection was detected. Normal liver tissues from patients 6 and 7, who died of pancreatic carcinoma and subarachnoid bleeding, respectively, were used as controls. Two human HCC cell lines, HuH-7 and HepG2, were obtained from the Japanese Cancer Research Resources Bank.
|
Culture of HuH-7 and HepG2 Cells.
Cells were seeded into 10-cm culture dishes containing DMEM (Life Technologies, Inc.) supplemented with 10% or 0.1% FBS. Culture medium was changed every other day during the experiment. Cells were trypsinized and counted at the times indicated in Fig. 4.
Cells harvested at the numbered points were used for cell cycle analysis or RNA extraction.
|
Sodium Butyrate Treatment.
HuH-7 cells were seeded in DMEM supplemented with 10% FBS and various concentrations of sodium butyrate (0–3 mM). After a 24-h incubation, cells were harvested, and total RNA was extracted.
RNA Extraction and RT.
RNA extraction was performed using ISOGEN (Nippon Gene) as recommended by the manufacturer. One µg of total RNA was added to 0.4 µg of oligodeoxythymidylic acid primer and brought to a final volume of 12 µl. The samples were heated at 70°C for 5 min and cooled to room temperature. The primer RNA mixture was combined with 40 units of Moloney murine leukemia virus reverse transcriptase (Superscript II; Life Technologies, Inc.), 10 mM DTT, 1 mM each of the four deoxynucleoside triphosphates, and reaction mixture as described in the instruction manual. The RT reaction was then carried out at 42°C for 60 min.
cDNA Probes.
The probes used for the Northern hybridization were generated by RT-PCR amplification using the following primer pairs: (a) 5'-CTATGTGCCTCCCACAGG-3' and 5'-TTGGCGTAAACCTTGAAGCG-3' for Gal-4; (b) 5'-ACGTCTGAGGCTGGAAGC-3' and 5'-TTTCCATGTACAATGTGTGA-3' for UGT2B4; (c) 5'-GTTACCCTGCTTTGCCTCG-3' and 5'-CTTTGTCAGAGACATCCACG-3' for dek; (d) 5'-CTCTTCCAAAGCTCCTGC-3' and 5'-CAACTATCACCACAGGTAGC-3' for IGFBP-1; (e) 5'-GGCCGCAACCAGAACTCC-3' and 5'-AGGGTCCACAGTGTCCAC-3' for vitronectin; (f) 5'-GTTTGTGACCTCCAGGCAG-3' and 5'-CTGGGCTTTCCTTCCTGAG-3' for RIG-E; (g) 5'-CCTCAGCTTGCTGTCTCAG-3' and 5'-TCATCCACCACCAAGCTGC-3' for AFP; and (h) 5'-AGTCAAGGGATGGCACCG-3' and 5'-CTCACACTGATTTGGTCACC-3' for CYP3A4. PCR was performed using 1.5 µl of the RT products from HCC or liver tissues using a Taq polymerase amplification system (Pharmacia) with a denaturing temperature of 96°C (30 s), an annealing temperature of 54°C (1 min), and an extension temperature of 72°C (1 min) for 25 cycles. A cDNA fragment encompassing from bp 728–891 of human rpP0 (GenBank accession number M17885) was isolated by the differential display method. A cDNA encoding full-length human cyclin A was a gift from Dr. Steven I. Reed (The Scripps Research Institute, La Jolla, CA).
Northern Blot Analysis.
Ten µg of total RNAs were denatured and electrophoresed in a 1.2% agarose gel containing 0.66 M formaldehyde. Probe labeling and hybridization were performed as described previously (22)
. Specific band intensity was measured using Fuji imaging analysis system BAS-2000 (Fuji Film).
PCR Assay for CYP3A4 and CYP3A7 mRNAs.
RT products were PCR-amplified with oligonucleotide primers specific to human CYP3A4 (5'-CTCTTCAAGAAATCTGTGCCTG-3' and 5'-GGGTGGTGGAAATAGTCCCG-3') and CYP3A7 (5'-CTCTTTAAGAAAGCTGTGCCCC-3' and 5'-GGGTGGTGGAGATAGTCCTA-3') or, as a control, ß2-microglobulin (5'-ATCCAGCGTACTCCAAAGAT-3' and 5'-TTACATGTCTCGATCCCACT-3') as described above, except that the amplification was carried out for 20 cycles in the presence of 0.2 MBq of [
-32P]dCTP. The amplified cDNAs were separated on a 4% polyacrylamide gel, transferred onto Whatman 3MM paper, and dried.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Among 50,515 and 50,472 transcripts, which represented 20,534 and 15,163 different genes derived from HCC and nontumorous liver tissues, respectively, we picked 150 known transcripts that occurred at least six times in either of the profiles and showed differences more than five times between the two profiles. Among them, 28 were reproducibly overexpressed in HCC, whereas 2 were in nontumorous liver in the RT-PCR analysis using samples from patient 1. However, of the 28 transcripts mentioned above, 22 were excluded from further analysis because they were expressed more abundantly in liver tissue than in tumor tissues from other HCC patients (data not shown). Accordingly, we focused on the following eight transcripts: Gal-4, UGT2B4, IGFBP-1, vitronectin, rpP0, and dek, which were more abundant in HCC than in nontumorous liver tissue, and CYP3A4 and RIG-E, of which the reverse was true (Table 1)
.
|
. On the other hand, the expression of RIG-E mRNA (1.3 kb) was higher in all five nontumorous liver tissues than in the matched HCC tissues.
Radiointensity of each mRNA was measured, and the H:L ratios from five patients were plotted against histological grades in Fig. 2
. The mean H:L ratios for UGT2B4, rpP0, dek, and vitronectin mRNAs, respectively, were lowest in a well to moderately differentiated (Edmondson I or II) HCC from patient 5, intermediate in moderately differentiated HCCs (Edmondson II) from patients 1 and 4, and highest in the moderate to poorly differentiated (Edmondson II or III) samples from patients 2 and 3. Conversely, the mean H:L ratio for RIG-E mRNA was higher in patient 5, and lower in patients 2 and 3. However, the H:L ratios for IGFBP-1 and Gal-4 in moderately differentiated samples fluctuated widely, hence no correlation with the histological grading was observed.
|
suffered from HCV infection or liver cirrhosis (see "Materials and Methods"), nontumorous liver tissues in HCC patients are not normal but rather may be precancerous. Therefore, in such tissues, gene expression may not represent the normal status. Therefore mRNA expression was examined using virus-negative, normal liver samples from patients who died of pancreatic carcinoma (patient 6) and subarachnoid bleeding (patient 7). The levels of Gal-4, UGT2B4, rpP0, dek, IGFBP-1, vitronectin, and RIG-E mRNAs in normal liver were similar to those in nontumorous liver tissue from five HCC-bearing patients. In contrast, CYP3A4 expression was undetectably low in normal liver tissues from two non-HCC patients.
Because the nucleotide sequence of CYP3A4 is highly similar to but distinct from that of CYP3A7 (23)
, we may not be able to distinguish between these messages in the same Northern blot using a probe encoding CYP3A4 cDNA. Therefore, as an additional experiment, we designed primers specific for both CYP3A4 and CYP3A7 and performed RT-PCR analysis using the same RNA samples as used for Northern analysis. As shown in Fig. 3
, the levels of CYP3A4 relative to ß2-microglobulin, an internal control, were higher in both nontumorous liver and carcinoma tissues of HCC patients than in normal liver from a non-HCC patient. The overall expression pattern was quite similar to that obtained from the Northern blot analysis in Fig. 1
, suggesting that CYP3A4 is the major species represented by the hybridization signal with the CYP3A4 probe. On the other hand, the expression of CYP3A7 was generally much lower. Although its levels were also higher in liver tissues of HCC patients than in normal liver, the pattern of expression was distinct from that of CYP3A4. We confirmed by direct sequencing analysis that these selective primer pairs successfully amplified the predicted portions of the CYP3A4 and CYP3A7 cDNAs (data not shown). From these results, we concluded that the expression of both CYP3A4 and CYP3A7 was higher in liver tissues of HCC patients than in normal liver of non-HCC patients.
|
Expression of mRNAs in HCC Cell Lines under Different Growth Conditions.
The levels of cyclin A mRNA, as an indicator of proliferating cells in primary liver cancer (24)
, were significantly higher in all five HCC samples than in matched nontumorous liver tissue (Fig. 1)
, suggesting the high proliferating activity of HCC tissues. Therefore, the differences in the levels of mRNA expression observed between HCC and nontumorous liver may simply reflect the growth states of cells in these tissues. The expression was therefore examined in HCC cell lines under different growth conditions. As indicated in Fig. 4A
, HuH-7 and HepG2 cells grew rapidly in 10% FBS until they formed a confluent monolayer (approximately 3.5 x 106 cells). The growth rate was then markedly reduced when the cells started piling up. In subconfluent cultures grown in medium containing 0.1% serum, both cell lines also showed slower growth, but the growth rate was not as slow as that of the overcrowded cells. Cell cycle analysis demonstrated that the proportion of G0/G1-phase cells increased whereas that of S-phase cells decreased when rapidly growing cells became overcrowded or were seeded in 0.1% serum, respectively (Fig. 4B)
. Thus, cell cycle distribution agreed well with the growth rate of these cell lines.
Northern blot analysis using total RNAs indicated that the levels of cyclin A mRNAs were high in rapidly growing HuH-7 and HepG2 cells in 10% serum (Lanes 1 and 2 in Fig. 4C
), whereas they were significantly suppressed in growth-inhibited cells at higher cell density (Lane 3) and undetectable in normal liver tissue (Lane N). However, cyclin A mRNA was not markedly reduced in 0.1% serum (Lane 4). On the other hand, the levels of dek mRNA were higher in both rapidly growing and growth-inhibited cells in 10% and 0.1% serum, respectively (Lanes 1, 2, and 4), than in overcrowded cells (Lane 3). The expression was barely detectable in normal liver tissue (Lane N). These expression levels were analyzed quantitatively using the BAS-2000 to compare radiointensity, revealing an intimate correlation with the levels of cyclin A (P < 0.025, F test; data not shown). Unexpectedly, in rapidly growing HuH-7 and HepG2 cells, the levels of Gal-4, UGT2B4, and IGFBP-1 mRNAs were undetectably low, whereas the RIG-E level was as high as that in normal liver (Lanes 1 and 2). The level of IGFBP-1 could be even lower in HCC than in normal liver tissue (compare Lanes N and 1). Conversely, the levels of Gal-4, UGT2B4, and IGFBP-1 were significantly up-regulated, whereas that of RIG-E was suppressed in growth-inhibited cells at a higher cell density (Lane 3), although the expression of Gal-4 and UGT2B4 was exclusively observed only in HuH-7 or HepG2 cells, respectively. Furthermore, the levels of Gal-4 and IGFBP-1 mRNAs were also up-regulated, although RIG-E mRNA expression remained at a high level in low serum (Lane 4). Meanwhile, rpP0 mRNA expression was constitutively high under all growth conditions in these cells. On the other hand, vitronectin and CYP3A mRNAs were undetectable irrespective of the growth state of these cells (data not shown).
These results suggest that the expression of dek mRNA was growth-regulated, whereas that of rpP0, Gal-4, hLS-2, IGFBP-1, and RIG-E mRNAs was not simply associated with the cell growth rate. Our results demonstrate that the expression of Gal-4, hLS-2, and IGFBP-1 mRNAs was induced, whereas expression of RIG-E mRNA was suppressed in overcrowded HCC cells, despite a marked reduction in their growth rate. In addition, the expression of Gal-4 and IGFBP-1 mRNAs was also induced in low serum, whereas high levels of rpP0 mRNA in HCC cells appeared to be independent of the growth conditions.
Expression of mRNAs in HuH-7 Cells Treated with Sodium Butyrate.
Our results in Fig. 2
suggest that the expression of some isolated cDNAs could be associated with the differentiation status of HCC cells. To evaluate whether the mRNA expression is correlated with liver cell differentiation, Northern blot analysis was performed using total RNAs from HuH-7 cells treated with sodium butyrate, an inducer of differentiation of HCC cells (25)
. As shown in Fig. 5
, the mRNA level of dek was reduced by butyrate in a dose-dependent manner, similar to that of AFP mRNA, which is used as a differentiation marker, whereas the mRNA level of RIG-E was increased dose-dependently. Interestingly, the level of IGFBP-1 mRNA was enhanced at lower doses (up to 1 mM) but significantly reduced at higher dose (3 mM) of sodium butyrate. However, the expression of rpP0 mRNA was unaffected by butyrate. Gal-4 and UGT2B4 mRNAs were also unaffected by butyrate in confluent HuH-7 and HepG2 cells (data not shown). These results suggest that the high levels of dek and the low levels of RIG-E mRNAs are correlated with dedifferentiation of HCC cells, whereas IGFBP-1 may be preferentially expressed in moderately differentiated HCC cells rather than in poorly or well-differentiated HCC and liver cells.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The expression of dek was growth-regulated because it was well synchronized with that of cyclin A, an S phase-specific cyclin. In contrast, the expression of Gal-4, UGT2B4, IGFBP-1, and RIG-E was cell density dependent. The expression of Gal-4, UGT2B4, and IGFBP-1 was induced and the expression of RIG-E was suppressed in dense, overcrowded conditions. Furthermore, high expression of IGFBP-1 and Gal-4 mRNAs was also induced by reducing the serum concentration. Similar density-dependent induction of the MN oncoprotein has been reported in HeLa cells (26) . In persistent nodules, focal proliferation could cause an increase of cell-cell interaction or growth factor shortage due to poor supply or increased consumption. Under such circumstances, a set of cell density-regulated genes may have critical roles in the manifestation of HCC cell phenotypes.
Galectins are a family of ß-galactoside-binding lectins with related amino acid sequences. They are soluble proteins and are generally localized in the cytosol. However, they can accumulate on the cell surface under certain conditions to play an important role in cell-cell and cell-matrix interactions. Gal-1 mRNA expression is elevated in fibrosarcoma cells (27) and squamous cell carcinoma (28) , whereas Gal-3 is overexpressed in thyroid tumors (29) , colon cancer (30) , and squamous cell carcinoma (28) . Furthermore, the introduction of a Gal-1 cDNA expression vector transforms BALB3T3 fibroblasts (31) , and the recombinant Gal-3 product stimulates the growth of lung fibroblasts (32) . However, there has been no previous report about the association between Gal-4 and liver malignancy. In contrast to our results in liver, Gal-4 expression is down-regulated in colon carcinoma (33) , suggesting that the tissue-specific background is important in determining the functional significance of this molecule for tumor development.
UGTs play a major role in the detoxification of chemicals including carcinogens, and are separated in two families, designated UGT1 and 2, in which UGT2B4 gene belongs (34) . UGT2B4 gene could also have mutated sub-isoforms (35 , 36) . In contrast to our observation of UGT2B4 expression, down-regulation of several UGT1A genes are demonstrated in HCCs (37) . Since UGTs could also render resistance to anticancer drugs (38) , differences in the substrate specificity of these isoformes could be important to determine the effects on the liver carcinogenesis.
In line with our results, increased expression of rpP0 has been reported in HCC as well as in colon carcinoma cells (39) . Our results further suggest that the expression of this gene may not simply be correlated with growth states. Meanwhile, rpP0 is thought to interact with eukaryotic elongation factors (40) . Because the eukaryotic translational initiation factor 4 transforms NIH3T3 cells when the mRNA is overexpressed (41) , rpP0 may also have a causal effect on HCC progression via the translational machinery.
DEK is first identified in a fusion with CAN nucleoporin protein in a subtype of acute myelogenous leukemia (42) . The product of the nonrearranged dek gene is a DNA-binding nuclear protein that can recognize a specific element in the HIV-2 enhancer (43) . Our results demonstrated that the expression of dek was S-phase dependent, suggesting its involvement in DNA synthesis. It is of particular interest that a G1-S phase cell cycle checkpoint defect in D-type AT is, in part, complemented by a NH2-terminal-truncated dek product (44) . Because the ATM (mutated in the disease AT) gene functions upstream of the p53 antioncogene (45) , these observations imply that endogenous DEK may have an oncogenic effect by inhibiting p53.
IGFBPs are present in extracellular fluids and can modulate the binding of IGF to its receptor (46) . We observed that IGFBP-1 mRNA was induced in low serum. This is probably consistent with the fact that IGF-I or insulin in serum can suppress IGFBP-1 expression in HCC cells (47) . Furthermore, it has been reported that the level of IGF-I mRNA in HCC is lower than that in nontumorous liver (48) . These observations, together with our results, suggest that the levels of IGF-I and IGFBP-I mRNAs are inversely regulated in both HCC and nontumorous liver. Interestingly, butyrate optimally stimulated IGFBP-1 expression at about 1 mM but repressed it at 3 mM. Our observation using tissue samples demonstrated that the highest H:L ratio was observed in moderately differentiated HCC, although the ratios fluctuated widely among the samples. Accordingly, IGFBP-1 mRNA may be preferentially expressed in moderately differentiated HCC cells compared to either poorly differentiated or well-differentiated HCC or nontumorous liver cells. This hypothesis is, in part, supported by the observation that IGFBP-1 mRNA is lower in poorly differentiated rat hepatoma cells than in differentiated cells (49) .
IGFBP-1 expression is up-regulated in the liver during postinjury regeneration (50)
, and autocrine growth regulation of HCC cells involving IGF-I and its receptor has been suggested (51)
. Thus, IGFBP-1 may be a modulator of liver cell proliferation. There are two isoforms of IGFBP-1: (a) the phosphorylated form has high affinity for IGF and inhibits stimulation of DNA synthesis by IGF; and (b) conversely, the nonphosphorylated form has a low affinity for IGF and enhances the activity of IGF (46)
. Furthermore, IGFBP-1 binds specifically to the 5ß1 integrin receptor and can stimulate cell migration in the absence of IGF activity (46)
. These results suggest that this molecule may regulate the metastasis and invasiveness as well as the proliferation of HCC cells.
Vitronectin has been identified as an adhesive protein that promotes the attachment and spreading of normal cells and neoplastic cells in vitro. This activity is mediated through an Arg-Gly-Asp adhesion sequence (52) . Liver cells are considered to be the principal source of plasma vitronectin. Poorly differentiated HCC is characterized by up-regulation of vitronectin together with other components of the extracellular matrix (53) . In line with this, we observed higher levels of vitronectin mRNA in higher-grade HCC than in lower-grade HCC or nontumorous liver tissues. This molecule is accumulated in the interface between the tumor and invaded tissues and within cancerous sinusoids (53) , suggesting its stimulatory role in invasion and metastasis of HCC cells.
RIG-E was originally isolated as a transcript induced in promyelocytic leukemia cells by all-trans-retinoic acid (54) . Our results demonstrate that this transcript is also up-regulated by sodium butyrate in HCC cells. Retinoic acid induces RAR-ß gene expression in hepatoma cells (55) , and overexpression of RAR-ß results in spontaneous differentiation or antiproliferation of hepatoma cells (56) . The RIG-E product may be an effecter for the antioncogenic activity of RARs. RIG-E encodes a human homologue of mouse differentiation antigen TSA-1/Sca-2, a member of the family of Ly-6 lymphocyte differentiation antigens (57) . The members of this family are small, cysteine-rich, GPI-anchored proteins that are differentially expressed in hematopoietic cell lines and appear to function in signal transduction, cell-cell adhesion, and cell-matrix attachment (58) . Therefore, down-regulation of the RIG-E protein in overcrowded and/or dedifferentiated HCC cells may result in the remodeling of cell-cell or cell-matrix association to facilitate further HCC progression.
The cytochrome enzymes are a superfamily of hemeproteins that are important in the oxidative, peroxidative, and reductive metabolism of endogenous compounds and participate in the chemical carcinogenesis process (59) . We observed that CYP3A4 mRNA was highly induced in nontumorous liver and maintained at variable levels in carcinoma tissues from HCC patients but barely detectable in normal liver from non-HCC patients. This expression does not seem to be caused by virus infection, because it was also highly expressed in samples from patient 5, who was HCV and HBV negative. We also detected minor expression of another cytochrome gene, CYP3A7 (23) , in liver tissues from HCC patients. This mRNA was originally identified in fetal liver and is developmentally regulated along with CYP3A4 (60) , although the expression of CYP3A7 mRNA is not restricted to the fetus (61) . Because these two transcripts are very similar (more than 92% nucleotide identity), we used a selective RT-PCR method to distinguish them. CYP3A4 and CYP3A7 mediate the metabolism of Ahepatocarcinogens, including mycotoxins (62) , 2,4-dichlorophenol (63) , and aflatoxin B1 (64 , 65) , and their overexpression increases aflatoxin-induced mutations (66) including those in the p53 tumor suppressor gene (67) . In addition, in inflammatory liver disease, a series of CYP transcripts are overexpressed (68) . These findings, together with our observations, suggest that CYP3A4 and CYP3A7 may be involved in chronic liver disease and cause the initiation process of liver carcinogenesis. However, their function may not be essential in HCC cells because their expression was maintained at variable levels in HCC tissues and barely detectable in several HCC cell lines (data not shown).
In conclusion, the expression of these mRNAs could be an index for the growth or differentiation of HCC cells or a histological feature of hepatic nodules with compacted tumor cells. Functional analysis of these transcripts should provide a wealth of information with which to further understand liver carcinogenesis.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Department of Biochemistry II, National Defense Medical College, Tokorozawa-shi, Saitama 359-8513, Japan. 
2 The abbreviations used are: HCC, hepatocellular carcinoma; UGT, UDP-glucuronosyltransferase; RIG-E, retinoic acid-induced gene E; Gal-4, galectin-4; rpP0, ribosomal phosphoprotein P0; IGFBP, insulin-like growth factor-binding protein; IGF-I, insulin-like growth factor-1; FBS, fetal bovine serum; RT, reverse transcription; AFP, -fetoprotein; RAR, retinoic acid receptor; AT, ataxia-telangiectasia; H:L, HCC:nontumorous liver; HCV, hepatitis C virus; HBV, hepatitis B virus; GPI, glycosylphosphatidylinositol.
Received 3/ 1/99. Accepted 7/30/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology, 107: 499-504, 1994.[Medline]
This article has been cited by other articles:
|
|
 |
|
  T. M. Wise-Draper, R. A. Mintz-Cole, T. A. Morris, D. S. Simpson, K. A. Wikenheiser-Brokamp, M. A. Currier, T. P. Cripe, G. C. Grosveld, and S. I. Wells Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo Cancer Res., March 1, 2009; 69(5): 1792 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wu, J. Zuo, G. Ji, H. Saiyin, X. Liu, F. Yin, N. Cao, Y. Wen, J. J. Li, and L. Yu Proapoptotic Function of Integrin {beta}3 in Human Hepatocellular Carcinoma Cells Clin. Cancer Res., January 1, 2009; 15(1): 60 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Wise-Draper, R. J. Morreale, T. A. Morris, R. A. Mintz-Cole, E. E. Hoskins, S. J. Balsitis, N. Husseinzadeh, D. P. Witte, K. A. Wikenheiser-Brokamp, P. F. Lambert, et al. DEK Proto-Oncogene Expression Interferes with the Normal Epithelial Differentiation Program Am. J. Pathol., January 1, 2009; 174(1): 71 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kappes, J. Fahrer, M. S. Khodadoust, A. Tabbert, C. Strasser, N. Mor-Vaknin, M. Moreno-Villanueva, A. Burkle, D. M. Markovitz, and E. Ferrando-May DEK Is a Poly(ADP-Ribose) Acceptor in Apoptosis and Mediates Resistance to Genotoxic Stress Mol. Cell. Biol., May 15, 2008; 28(10): 3245 - 3257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Abba, H. Sun, K. A. Hawkins, J. A. Drake, Y. Hu, M. I. Nunez, S. Gaddis, T. Shi, S. Horvath, A. Sahin, et al. Breast Cancer Molecular Signatures as Determined by SAGE: Correlation with Lymph Node Status Mol. Cancer Res., September 1, 2007; 5(9): 881 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scoumanne and X. Chen The Lysine-specific Demethylase 1 Is Required for Cell Proliferation in Both p53-dependent and -independent Manners J. Biol. Chem., May 25, 2007; 282(21): 15471 - 15475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mor-Vaknin, A. Punturieri, K. Sitwala, N. Faulkner, M. Legendre, M. S. Khodadoust, F. Kappes, J. H. Ruth, A. Koch, D. Glass, et al. The DEK Nuclear Autoantigen Is a Secreted Chemotactic Factor Mol. Cell. Biol., December 15, 2006; 26(24): 9484 - 9496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Wise-Draper, H. V. Allen, E. E. Jones, K. B. Habash, H. Matsuo, and S. I. Wells Apoptosis Inhibition by the Human DEK Oncoprotein Involves Interference with p53 Functions Mol. Cell. Biol., October 15, 2006; 26(20): 7506 - 7519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hu, Z. Zhang, J. W. Kim, Y. Huang, and T. J. Liang Altered Proteolysis and Global Gene Expression in Hepatitis B Virus X Transgenic Mouse Liver J. Virol., February 1, 2006; 80(3): 1405 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Wise-Draper, H. V. Allen, M. N. Thobe, E. E. Jones, K. B. Habash, K. Munger, and S. I. Wells The Human DEK Proto-Oncogene Is a Senescence Inhibitor and an Upregulated Target of High-Risk Human Papillomavirus E7 J. Virol., November 15, 2005; 79(22): 14309 - 14317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cleary, K. V. Sitwala, M. S. Khodadoust, R. P. S. Kwok, N. Mor-Vaknin, M. Cebrat, P. A. Cole, and D. M. Markovitz p300/CBP-associated Factor Drives DEK into Interchromatin Granule Clusters J. Biol. Chem., September 9, 2005; 280(36): 31760 - 31767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Böhm, F. Kappes, I. Scholten, N. Richter, H. Matsuo, R. Knippers, and T. Waldmann The SAF-box domain of chromatin protein DEK Nucleic Acids Res., February 18, 2005; 33(3): 1101 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Loeppen, C. Koehle, A. Buchmann, and M. Schwarz A {beta}-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors Carcinogenesis, January 1, 2005; 26(1): 239 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Hansel, A. Rahman, M. House, R. Ashfaq, K. Berg, C. J. Yeo, and A. Maitra Met Proto-Oncogene and Insulin-Like Growth Factor Binding Protein 3 Overexpression Correlates with Metastatic Ability in Well-Differentiated Pancreatic Endocrine Neoplasms Clin. Cancer Res., September 15, 2004; 10(18): 6152 - 6158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, Y. Xie, J. M. Ward, B. A. Diwan, and M. P. Waalkes Toxicogenomic Analysis of Aberrant Gene Expression in Liver Tumors and Nontumorous Livers of Adult Mice Exposed in utero to Inorganic Arsenic Toxicol. Sci., February 1, 2004; 77(2): 249 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Evans, B. L. Gallie, M. A.S. Jewett, G. R. Pond, K. Vandezande, J. Underwood, Y. Fradet, G. Lim, P. Marrano, M. Zielenska, et al. Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction Am. J. Pathol., January 1, 2004; 164(1): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Campillos, M. A. Garcia, F. Valdivieso, and J. Vazquez Transcriptional activation by AP-2{alpha} is modulated by the oncogene DEK Nucleic Acids Res., March 1, 2003; 31(5): 1571 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Leu, M. A. S. Crissey, L. E. Craig, and R. Taub Impaired Hepatocyte DNA Synthetic Response Posthepatectomy in Insulin-Like Growth Factor Binding Protein 1-Deficient Mice with Defects in C/EBP{beta} and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Regulation Mol. Cell. Biol., February 15, 2003; 23(4): 1251 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takahashi, N. Seki, T. Ozaki, M. Kato, T. Kuno, T. Nakagawa, K.-i. Watanabe, K. Miyazaki, M. Ohira, S. Hayashi, et al. Identification of the p33ING1-regulated Genes that Include Cyclin B1 and Proto-oncogene DEK by Using cDNA Microarray in a Mouse Mammary Epithelial Cell Line NMuMG Cancer Res., April 1, 2002; 62(8): 2203 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ideo, A. Seko, T. Ohkura, K. L. Matta, and K. Yamashita High-affinity binding of recombinant human galectin-4 to SO3-->3Gal{beta}1->3GalNAc pyranoside Glycobiology, March 1, 2002; 12(3): 199 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zembutsu, Y. Ohnishi, T. Tsunoda, Y. Furukawa, T. Katagiri, Y. Ueyama, N. Tamaoki, T. Nomura, O. Kitahara, R. Yanagawa, et al. Genome-wide cDNA Microarray Screening to Correlate Gene Expression Profiles with Sensitivity of 85 Human Cancer Xenografts to Anticancer Drugs Cancer Res., January 1, 2002; 62(2): 518 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-G Scharf, F Dombrowski, and G Ramadori The IGF axis and hepatocarcinogenesis Mol. Pathol., June 1, 2001; 54(3): 138 - 144. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Kjoller and A. Hall Rac Mediates Cytoskeletal Rearrangements and Increased Cell Motility Induced by Urokinase-Type Plasminogen Activator Receptor Binding to Vitronectin J. Cell Biol., March 19, 2001; 152(6): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Ghoshal, Z. Xu, G. A. Wood, and M. C. Archer Induction of Hepatic Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) in Rats by Dietary n-6 Polyunsaturated Fatty Acids Experimental Biology and Medicine, November 1, 2000; 225(2): 128 - 135. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Chatterjee, S. Singh, R. Sohoni, N. J. Singh, A. Vaidya, C. Long, and S. Sharma Antibodies against Ribosomal Phosphoprotein P0 of Plasmodium falciparum Protect Mice against Challenge with Plasmodium yoelii Infect. Immun., July 1, 2000; 68(7): 4312 - 4318. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
) FBS-containing medium. Ordinate, relative cell numbers; abscissa, hours when cells were harvested. Cells harvested at the indicated times were used for cell cycle analysis (B) and Northern blot analysis (C). B, cell cycle analysis of HuH-7 and HepG2 cells corresponding to the growth conditions 1, 3, and 4 in A. C, Northern blot analysis using total RNAs from HuH-7 and HepG2 cells in different growth states. Ten µg of total RNAs extracted from cells at the points from 1–4 in A and, as a control, RNA from normal liver (N) of patient 7 (Fig. 1)
; patient 4, 
; patient 5, 
.
